摘要
目的评价高危型HPV分型（HR-HPV-DNA）检测联合TCT技术（液基薄层细胞学检查）在子宫颈癌及其癌前病变筛查中的临床价值。方法选取2010年1月至2015年1月于本院门诊进行妇女体检自愿接受筛查的患者1862例，对任何一项阳性皆行阴道镜多点活检，以病理组织学为金标准。将TCT和HR-HPV-DNA结果的单独应用及两种方案联合应用与组织学诊断结果作比较分析。结果本研究1092例标本中，HR-HPV-DNA检测阳性203例（18．59％），TCT检测阳性157例（14．38％），联合检测阳性67例（6．14％）；HR-HPV-DNA检测阳性符合率低于TCT检测，联合检测阳性符合率明显高于单独HR-HPV-DNA检测和单独TCT检测，差异均有统计学意义（P〈0．05）；276例患者因TCT检测、HR-HPV-DNA检测阳性而进行阴道镜下病理活检，随着病理结果的级别升高，HR-HPV-DNA感染率也逐渐升高（P〈0．05）；157例TCT检查阳性患者中，随着细胞学诊断级别升高，TCT阳性检出率、HR-HPV-DNA检出率也明显升高（P〈0．05）。结论高危型HPV分型联合TCT技术检测可以提高宫颈癌和癌前病变筛查的准确性。
Objective To evaluate the value of High-risk HPV genotyping technology （HR-HPV- DNA） combined with TCT for screening cervical cancer and precancerous lesions. Methods 1 862 women taking physical check and willing to take the screening at the outpatient department of our hospital from January, 2010 to January, 2015 were selected. The women positive in any one indicator took multi-spot biopsy under colposcope. And histopathology was the gold standard. The results of TCT, HR-HPV-DNA, or the combination ofthese two were compared with that ofhistological diagnosis. Results Amongthe 1 092 specimens, HR-HPV- DNA showed that 203 cases （18.59%） was positive, TCT 157 cases （14.38%）, and HR-HPV-DNA combined with TCT 67 cases （6.14%）. The positive coincidence rate of HR-HPV-DNA was lower than that of TCT and that of the combination was obviously higher than those of HR-HPV-DNA and TCT, with statistical differences （P〈0.05）. 276 patients positive in TCT or HR-HPV-DNA underwent colposcopic biopsy; the results showed that HR-HPV-DNA detection rate increased with the levels of pathological findings （P〈0.05）. Among the 157 patients positive in TCT, the TCT positive rate and HR-HPV-DNA detection rate increased with cytological diagnosis level （P〈0.05）. Conclusion High-risk HPV genotyping technology combined with TCT can increase the accuracy in screening cervical cancer and precancerous lesions.
出处
《国际医药卫生导报》
2016年第8期1064-1067,共4页
International Medicine and Health Guidance News
